Nomogram to Predict Outcomes After Staged Revascularization in ST-Segment Elevation Myocardial Infarction and Multivessel Coronary Artery Disease

Huaigen Wang,Aiqun Ma,Tingzhong Wang
DOI: https://doi.org/10.2147/ijgm.s457236
IF: 2.145
2024-04-30
International Journal of General Medicine
Abstract:Huaigen Wang, 1 Aiqun Ma, 1, 2 Tingzhong Wang 1, 2 1 Department of Cardiovascular Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, People's Republic of China; 2 Shaanxi Key Laboratory of Molecular Cardiology (Xi'an Jiaotong University), Xi'an, Shaanxi, People's Republic of China Correspondence: Aiqun Ma; Tingzhong Wang, Email ; Objective: Approximately 50% of ST-segment elevation myocardial infarction (STEMI) patients have multivessel coronary artery disease (MVD). The management strategy for these patients remains controversial. This study aimed to develop predictive models and nomogram of outcomes in STEMI patients with MVD for better identification and classification. Methods: The least absolute shrinkage and selection operator (LASSO) method was used to select the features most significantly associated with the outcomes. A Cox regression model was built using the selected variables. One nomogram was computed from each model, and individual risk scores were obtained by applying the nomograms to the cohort. After regrouping patients based on nomogram risk scores into low- and high-risk groups, we used the Kaplan–Meier method to perform survival analysis. Results: The C-index of the major adverse cardiovascular event (MACE)-free survival model was 0· 68 (95% CI 0· 62– 0· 74) and 0· 65 [0· 62– 0· 68]) at internal validation, and that of the overall survival model was 0· 75 (95% CI 0· 66– 0· 84) and (0· 73 [0· 65– 0· 81]). The predictions of both models correlated with the observed outcomes. Low-risk patients had significantly lower probabilities of 1-year or 3-year MACEs (4% versus 11%, P = 0.003; 7% versus 15%, P =0.01, respectively) and 1-year or 3-year all-cause death (1% versus 3%, P =0.048; 2% versus 7%, respectively, P =0.001) than high-risk patients. Conclusion: Our nomograms can be used to predict STEMI and MVD outcomes in a simple and practical way for patients who undergo primary PCI for culprit vessels and staged PCI for non-culprit vessels. Keywords: ST-segment elevation myocardial infarction, multivessel coronary artery disease, percutaneous coronary intervention, major adverse cardiovascular events, all-cause death Acute coronary syndrome (ACS) is a common critical cardiovascular disease and a leading cause of death worldwide. 1,2 ST-segment elevation myocardial infarction (STEMI) accounts for ~36% of ACS cases. 3 STEMI is defined as a combination of persistent ST-segment elevation on electrocardiogram and the subsequent release of biomarkers of myocardial necrosis. 4 Previous studies have shown that approximately half of STEMI patients have multivessel coronary artery disease (MVD). MVD increases the risk of recurrence and short-term death after percutaneous coronary intervention (PCI) and is an important cause of poor prognosis in STEMI patients. 5,6 The first-line treatment for STEMI patients is timely primary PCI (PPCI) for culprit vessels. 4 However, the presence of non-culprit vessels makes the treatment more complicated for patients with MVD. The management strategy and its impact on patient prognosis for non-culprit vessels are still controversial. The COMPLETE trial confirmed that complete revascularization was superior to culprit-lesion-only PCI in patients with STEMI and MVD. 7 However, intervention strategies for non-culprit vessels, such as the optimal timing of intervention, are not very consistent. Previous retrospective studies reported inconsistent results due to the enrollment of different populations and different sample sizes. 8–10 This suggests that this population is highly heterogeneous, and further assessment and classification are needed. Therefore, this study aimed to develop predictive models of major adverse cardiovascular events (MACEs) and all-cause mortality in patients with STEMI combined with MVD to better identify and classify these patients. We conducted a retrospective investigation. Nomograms were developed to predict outcomes after staged revascularization (SR) in acute STEMI and MVD patients using data from the First Affiliated Hospital of Xi'an Jiaotong University. All patients met the diagnostic criteria for acute STEMI. They all underwent PPCI for culprit vessels and staged PCI for non-culprit vessels. The exclusion criteria were as follows: (1) STEMI without PPCI or staged PCI and (2) acute non-STEMI or unstable angina. This study complies with the Declaration of Helsinki and was approved by the Ethics Committee of First Affiliated Hospital of Xi'an Jiaotong University. The informed consent was gained from the patients and their families. General data (age, se -Abstract Truncated-
medicine, general & internal
What problem does this paper attempt to address?